Safe Life Corp. announces the availability of the Safe Life A400 Series N95 Respirator with Antimicrobial Protection. The A400 is designed to be a comfortable, breathable respirator with the added protection of an active antimicrobial based on iodine, which has a nearly 200-year track record for being effective against a broad spectrum of microorganisms.
As the H1N1 influenza virus continues to spread around the world, the need for N95 respirators for healthcare workers and other occupational users is more critical than ever. Last month, the Centers for Disease Control and Prevention (CDC) reinforced its existing guidelines on respiratory protection by recommending the use of fit-tested, N95 respirators for healthcare personnel who are in close contact with patients with suspected or confirmed 2009 H1N1 influenza. Other global health organizations that have publicly supported N95 usage include the Institute of Medicine and the Ontario Ministry of Health.
According to Richard Jaffe, chairman and CEO of Safe Life, the A400 represents a significant technology advancement that addresses the major challenges healthcare workers and other occupational users have long faced when wearing N95 respirators. “In the past 20 years, little has changed in respirator design, which means healthcare workers and other occupational users have been forced to choose between the comfort and breathability of a surgical mask and the filtration power of an N95 respirator,” he said. “Now, with the A400, which looks and feels like a surgical mask yet has the full protection of a respirator, workers no longer have to make compromises when it comes to comfort, safety and patient care.”
Among the first healthcare providers to equip its employees with the new Safe Life N95 Respirator with Antimicrobial Protection is Scripps Health, a $2 billion, nonprofit community health system based in San Diego. To ensure proper protection during the H1N1 pandemic, Scripps is providing Safe Life’s A400 Series respirator to healthcare staff in high-risk settings at all of its five acute-care hospital campuses as well as 19 outpatient centers and clinics.
“The health and safety of Scripps Health employees and patients are top priorities,” said Chris Van Gorder, president and CEO of Scripps Health. “The availability of this new product enables us to maintain an ample supply of N95 respirators throughout the flu season and also reinforces an overarching commitment to workplace safety by providing our employees with a respirator that can be worn easily for an entire shift.”
he compact, flat-fold design of the Safe Life A400 minimizes storages requirements and makes it ideal for stockpiling. The Safe Life N95 Respirator with Antimicrobial Protection is available in two sizes: small/medium (model A430) and medium/large (model A450). Safe Life is ramping up production at its manufacturing facilities in Williston, Vt. and Ipoh, Malaysia, and has the capacity to produce more than 100 million A400 respirators in 2010. The A400 is available through most major healthcare distributors.
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.